BioStem Technologies (BSEM) vs Celularity (CELU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Celularity (CELU) has outperformed BioStem Technologies (BSEM) over the past year, losing 32.1% versus a loss of 45.0%. Over five years, BSEM leads with a +88.6% price change compared with -98.0% for CELU. BioStem Technologies is the larger company by market cap ($49.3 million vs $47.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BSEM | CELU |
|---|---|---|
| Share price | $2.64 | $1.46 |
| Market cap | $49.29M | $47.38M |
| 1-day change | +10.46% | -0.68% |
| YTD return | -30.71% | +31.53% |
| 1-year return | -45.00% | -32.09% |
| 5-year return | +88.57% | -97.97% |
| P/E ratio (TTM) | 3.00 | — |
| Forward P/E | 9.10 | — |
| EPS (TTM) | $0.88 | $-2.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $2.55 |
| 52-week low | $2.25 | $0.56 |
| Distance from 52-week high | -68.57% | -42.75% |
| Analyst consensus | none | — |
| Avg. price target upside | +165.15% | — |
| Average volume | 124.14K | 3.89M |
| Shares outstanding | 18.67M | 32.45M |
| Employees | 73 | 115 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CELU has outperformed BSEM by 12.9 percentage points over the past year.
About BioStem Technologies
BSEM stock →BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 73 employees
About Celularity
CELU stock →Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.
Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees
BSEM vs CELU FAQ
Which is bigger, BioStem Technologies or Celularity?
BioStem Technologies (BSEM) is larger, with a market capitalization of $49.29M compared with $47.38M for Celularity (CELU).
Which stock has performed better over the past year, BSEM or CELU?
CELU returned -32.09% over the past 12 months, compared with -45.00% for BSEM (price return, excluding dividends). Past performance does not predict future results.
Are BioStem Technologies and Celularity in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for BioStem Technologies and Biotechnology: Pharmaceutical Preparations for Celularity.